Cherry Hill, NJ, United States of America

Alexander Mazo

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Alexander Mazo in Epigenetic Remodeling

Introduction

Alexander Mazo is an accomplished inventor based in Cherry Hill, NJ (US). He has made significant contributions to the field of therapeutic treatments, particularly in the area of fibrosis prevention. With a total of 2 patents, Mazo's work focuses on innovative approaches to address complex medical challenges.

Latest Patents

Mazo's latest patents include a groundbreaking therapeutic treatment aimed at preventing or reducing the formation of fibrosis. This treatment involves administering a UTX or JMJD3 inhibitor to patients, which has shown effectiveness in preventing or reducing fibrosis in situations where access to injury or dysmorphogenetic tissues occurs before the fibrotic process becomes established. This innovative approach highlights Mazo's commitment to advancing medical science and improving patient outcomes.

Career Highlights

Mazo is currently affiliated with Thomas Jefferson University, where he continues to engage in research and development of novel therapeutic strategies. His work is characterized by a strong focus on epigenetic remodeling, which has the potential to transform the way fibrosis is treated in clinical settings.

Collaborations

Mazo collaborates with esteemed colleagues, including Janice L Walker and Svetlana Petruk. These partnerships enhance the research environment and foster innovation in their shared field of study.

Conclusion

Alexander Mazo's contributions to the field of epigenetic remodeling and fibrosis prevention are noteworthy. His innovative patents and collaborative efforts at Thomas Jefferson University position him as a key figure in advancing therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…